Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield Alabama site-of-service Pri…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - alabamaPolicy PH-9001

    Voluntary Site of Service Management Policy

    Customize your policy alerts

    Sign up for blue cross blue shield - alabama Policy PH-9001 alerts

    Get alerted when Policy PH-9001 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs voluntary management of site of care for members receiving select infused specialty medications, enabling transition from higher‑cost hospital outpatient settings to more cost‑effective alternate infusion locations when clinically appropriate. It applies to members and providers participating in the Provider‑Administered Drug Program with home health benefits.

    Policy Summary
    Payerblue cross blue shield - alabama
    PolicyVoluntary Site of Service Management Policy
    Policy CodePolicy PH-9001
    Change TypeNo material changes
    Effective DateJul 1, 2019
    Last ReviewAug 13, 2024
    Next Review DateAug 13, 2024
    Key ActionObtain prior authorization for all drugs in the Voluntary Site of Service Management program and coordinate transitions with Prime Therapeutics' Infusion Referral Center.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2019-07-01Program effective date
    Prior authAuthorization requirement
    Home healthEligibility requirement
    Prime IRCOperational partner

    Coverage Criteria

    Voluntary Site‑of‑Service Transition Criteria

    Covered when ALL of the following are met

    Eligibility and agreement: Member has sufficient home health benefits in place; member agrees to transition care to an alternate setting; prescriber is contacted and agrees to transition the member's infusion to an alternate place of treatment; prescriber approves that alternate place of treatment is clinically appropriate.

    IRC confirms these criteria prior to transition

    Member Identification

    Members will be managed when ANY of the following apply

    New utilisers and current users: New utilizers on or after July 1, 2019 with sufficient home health benefits will be managed; current utilizers may be offered participation upon prior authorization renewal or identification via paid claims reporting.

    Identification through prior authorization program or paid claims reporting

    Policy Summary
    Payerblue cross blue shield - alabama
    PolicyVoluntary Site of Service Management Policy
    Policy CodePolicy PH-9001
    Change TypeNo material changes
    Effective DateJul 1, 2019
    Last ReviewAug 13, 2024
    Next Review DateAug 13, 2024
    Key ActionObtain prior authorization for all drugs in the Voluntary Site of Service Management program and coordinate transitions with Prime Therapeutics' Infusion Referral Center.
    SourceLink
    On This Page
    Coverage CriteriaDrugs in Scope / CodingProvider Actions and AuthorizationDefinitionsSite of Care TransitionBackground

    Certain agents in the drugs‑in‑scope listing are specifically annotated for use only in non‑oncology diagnoses. For example, rituximab entries (J9312 and biosimilar/Q‑codes such as Q5119 and Q5115) are listed with the parenthetical note “non‑oncology diagnosis only.” This indicates that site‑of‑service management under this program applies to rituximab when used for non‑oncology indications, and oncology uses are outside the scope of the Voluntary Site‑of‑Service Management program for those codes.

    Drugs in Scope / Coding

    Drugs in Scope - group 1mixed
    J3262ACTEMRA / tocilizumab
    J0791ADAKVEO / crizanlizumab-tmca
    J1931ALDURAZYME / laronidase
    J1554ASCENIV / intravenous immune globulin
    Q5121AVSOLA / infliximab-axxq
    J0490BENLYSTA / belimumab
    J0597BERINERT / C1 esterase inhibitor
    J1556BIVIGAM / intravenous immune globulin
    J1786CEREZYME / imiglucerase
    J0717CIMZIA / certolizumab pegol
    1–10 of 20
    1/2
    Drugs in Scope - group 2mixed
    J1569intravenous immune globulin
    J1566GAMMAGARD S/D, CARIMUNE NF / intravenous immune globulin
    J1561GAMMAKED / intravenous immune globulin
    J1557GAMMAPLEX / intravenous immune globulin
    J1561GAMUNEX / intravenous immune globulin
    J1599IMMUNE GLOBULIN / intravenous immune globulin
    Q5103INFLECTRA / infliximab-dyyb
    J2840KANUMA / sebelipase alfa
    J0221LUMIZYME / alglucosidase alfa
    J1458NAGLAZYME / galsulfase
    1–10 of 20
    1/2
    Drugs in Scope - group 3mixed
    Q5104infliximab-abda
    J9312RITUXAN / rituximab ( non-oncology diagnosis only )
    Q5119RUXIENCE / rituximab-pvvr ( non-oncology diagnosis only )
    J1299SOLIRIS / eculizumab
    J3357STELARA / ustekinumab
    J3241TEPEZZA / teprotumumab-trbw
    J2356TEZSPIRE / tezepelumab-ekko
    J1746TROGARZO / ibalizumab-uiyk
    Q5115TRUXIMA / rituximab-abbs ( non-oncology diagnosis only )
    J2323TYSABRI / natalizumab
    1–10 of 14
    1/2

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization and Transition

    All drugs in the Voluntary Site of Service Management require prior authorization. Members will be identified through the Provider-Administered Drug prior authorization program or through paid claims reporting for current utilizers. Members with approved drug prior authorizations who are identified as receiving listed specialty drugs in a hospital outpatient setting will be transitioned internally to Prime Therapeutics' Infusion Referral Center (IRC) for potential movement to an alternate site of care.

    • All drugs in the Voluntary Site of Service Management require prior authorization
    • Members identified via PA program or paid claims reporting
    • Transition to Prime Therapeutics' IRC for members receiving listed specialty drugs in hospital outpatient setting
    Note

    Provider Actions

    Providers must coordinate with the IRC and the member's prescriber to facilitate any transition of infusion services. The provider should ensure eligibility of benefits, obtain required approvals, and supply clinical information requested by IRC to support the transition.

    • Contact IRC to initiate transition workflow
    • Confirm prescriber agreement and clinical appropriateness for alternate site of treatment
    • Provide clinical documentation and respond to IRC requests in a timely manner
    Documentation Required

    Nursing Precertification

    When required by the member's benefits, the home infusion provider is responsible for obtaining all necessary nursing precertifications prior to initiation of home infusion services.

    • Home infusion provider obtains nursing precertifications as specified by member benefits
    • Precertification must be secured before home infusion services begin to avoid delays or denials
    Denial Risk

    Prior Authorization Required

    Lack of required prior authorization may result in the member not being identified for transition, denial of payment, or other impacts to coverage and site-of-care management. Providers should verify PA approval before administering or billing for services.

    • Absence of PA can prevent identification for transition to IRC
    • Services provided without PA may be denied or subject to retrospective review
    • Verify prior authorization status before scheduling or delivering infusion services

    Definitions

    Voluntary Site of Service Management — definition and key facts
    DefinitionVoluntary Site of Service Management: program that manages transition of infusion site of care for select specialty medications from high‑cost hospital outpatient settings to more cost‑effective, clinically appropriate alternate settings (e.g., home infusion or other outpatient locations).
    Effective dateEffective July 1, 2019.
    ScopeApplies to members and providers in the Provider‑Administered Drug Program who have home health benefits and are receiving select infused specialty medications in a hospital outpatient setting.
    Identification methodsMembers identified via the Provider‑Administered Drug prior authorization program or through paid claims reporting for current utilizers.
    Operational partnerTransition of identified members is managed internally by Prime Therapeutics' Infusion Referral Center (IRC).
    IRC (Infusion Referral Center) — role and responsibilities
    DefinitionInfusion Referral Center (IRC): Prime Therapeutics' internal center that coordinates transition of members identified as receiving select specialty infusions in a hospital outpatient setting to alternate sites of care.
    Primary responsibilitiesConfirm member has sufficient home health benefits, obtain member agreement, contact prescriber for agreement, and verify clinical appropriateness of the alternate site before transition.
    Authorization roleCoordinates transitions for members with approved prior authorizations for drugs listed in section IV.
    Nursing precertificationWhen required, ensures the home infusion provider obtains necessary nursing precertifications as specified by the member's benefits.

    Site of Care Transition

    Note

    Offer transition from hospital outpatient to more cost‑effective alternate setting

    Members receiving select infused specialty medications in a hospital outpatient setting will be offered transition to a more cost‑effective alternate site of care (for example, home infusion or another outpatient setting) when they have sufficient home health benefits and both the member and prescriber agree; the IRC coordinates the transition.

    • IRC confirms member eligibility, member and prescriber agreement, and clinical appropriateness before effectuating transition.

    Background

    The Voluntary Site‑of‑Service Management program identifies members receiving select infused specialty medications in higher‑cost hospital outpatient settings and offers to transition eligible members to more cost‑effective alternate infusion locations (for example, home infusion or other outpatient sites). The program is intended to preserve clinical appropriateness while reducing site‑of‑care costs by coordinating transitions when members have adequate home health benefits and both the member and prescriber agree.

    Operationally, members are identified through the Provider‑Administered Drug prior authorization process or via paid claims reporting and then referred to Prime Therapeutics' Infusion Referral Center (IRC) for coordination. The IRC confirms member eligibility, obtains prescriber and member agreement, and verifies clinical appropriateness before managing the transition.